Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming to ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

(Reuters) -U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug ...

Investigators conducted polygraph interviews as part of the effort to determine what happened to Lilly and Jack Sullivan.

The company’s underlying business is thriving, with analysts projecting its market value could hit $1 trillion in the coming ...

LILLY — Lilly Chiropractic topped Imler’s Poultry, 11-2, behind three hits, including two doubles, from Brandon Ickes and ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...